Anna Reid

Home  >  Anna Reid

Study Coordinator

Anna Reid

Melanoma Discovery

Anna Reid is a Trial Coordinator in the Melanoma Discovery lab at the Harry Perkins Institute of Medical Research, where she supports clinical research focused on identifying prognostic markers for melanoma and other cancers. With a focus on studies in circulating tumour cells and cell-free DNA, the research is contributing to the development of more precise and personalised approaches to cancer monitoring and treatment.

Anna completed her Bachelor of Science (Honours) in 2008 at Murdoch University in Perth, Western Australia. She plays a key role in facilitating collaborative research efforts that bridge laboratory discovery and patient care.

Study Coordinator

Anna Reid

Melanoma Discovery

Selected Publications

  • Abed, A., Reid, A., Law, N., Millward, M., Gray, E. (2024). HLA-A01 and HLA-B27 Supertypes, but Not HLA Homozygocity, Correlate with Clinical Outcome among Patients with Non-Small Cell Lung Cancer Treated with Pembrolizumab in Combination with Chemotherapy. Cancers, 16(17), Article number 3102. https://doi.org/10.3390/cancers16173102.
  • Abed, A., Beasley, A., Reid, A., Law, N., Calapre, L., Millward, M., Lo, J., Gray, E. (2023). Circulating pre-treatment T-cell receptor repertoire as a predictive biomarker in advanced or metastatic non-small-cell lung cancer patients treated with pembrolizumab alone or in combination with chemotherapy. ESMO Open, 8(6), Article number 102066. https://doi.org/10.1016/j.esmoop.2023.102066.
  • Calapre, L., Giardina, T., Beasley, A., Reid, A., Stewart, C., Amanuel, B., Meniawy, T., Gray, E. (2023). Identification of TP53 mutations in circulating tumour DNA in high grade serous ovarian carcinoma using next generation sequencing technologies. Scientific Reports, 13(1), Article number 278. https://doi.org/10.1038/s41598-023-27445-2.
  • Beasley, A., De Bruyn, D., Calapre, L., Al-Ogaili, Z., Isaacs, T., Bentel, J., Reid, A., Dwarkasing, R., Pereira, M., Khattak, A., Meniawy, T., Millward, M., Brosens, E., De Klein, A., Chen, F., Kiliҫ, E., Gray, E. (2023). Detection of metastases using circulating tumour DNA in uveal melanoma. Journal of Cancer Research and Clinical Oncology, 149(16), 14953-14963. https://doi.org/10.1007/s00432-023-05271-3.
  • Warburton, L., Reid, A., Amanuel, B., Calapre, L., Millward, M., Gray, E. (2023). Detectable ctDNA at the time of treatment cessation of ipilimumab and nivolumab for toxicity predicts disease progression in advanced melanoma patients. Frontiers in Oncology, 13(2023), article number 1280730. https://doi.org/10.3389/fonc.2023.1280730.
  • Marsavela, G., McEvoy, A., Pereira, M., Reid, A., Al-Ogaili, Z., Warburton, L., Khattak, A., Abed, A., Meniawy, T., Millward, M., Ziman, M., Calapre, L., Gray, E. (2022). Detection of clinical progression through plasma ctDNA in metastatic melanoma patients: a comparison to radiological progression. British Journal of Cancer, 126(3), 401-408. https://doi.org/10.1038/s41416-021-01507-6.
Close Menu